Review D'Urzo, Maleki-Yazdi & McIvor in patients who are persistently symptomatic and/or
at high risk of COPD exacerbations. Here, we report results of a systematic literature search …

Chronic obstructive pulmonary disease (COPD) is a devastating illness characterized by
airway and systemic inflammation, progressive airway obstruction and exacerbations. It is a …

ABSTRACT The European Respiratory Society (ERS) International Congress was held in
Munich, Germany, on 6th-10th September 2014, and was a particularly important …

Introduction Discordance between real-world prescribing patterns and global treatment
guidelines for the treatment of chronic obstructive pulmonary disease (COPD) with inhaled …

In recent years, large treatment studies have been published in the field of chronic
obstructive pulmonary disease (COPD) and were supplemented by several post-hoc …

Anticholinergic and β2-agonist bronchodilators are the mainstay of drug therapy in chronic
obstructive pulmonary disease (COPD), but other treatments are also used and may have a …

Background: Most patients with moderate and severe chronic obstructive pulmonary disease
(COPD) receive long-acting bronchodilators (LABA) for symptom control. It is, however …

Novel pharmacotherapies introduce additional options to providers and patients in how to
best treat chronic obstructive pulmonary disease (COPD). Emerging data question the role …

Background Bronchodilators are first-line therapy for chronic obstructive pulmonary disease
(COPD). Several classes of bronchodilators are available, which may be used singly or in …

Chronic obstructive pulmonary disease (COPD) guidelines suggest using inhaled
corticosteroids (ICS) in patients with severe airflow limitation or those at high risk of …